Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present .invention is the use of known o.xazo.lidLnones to treat psoriasis, ai- ⁇ ritis and to reduce the toj ⁇ city of cancer chemotherapy.
• Psoriasis is a we.ll .known condition, a pro.liferative disease of the sl ⁇ n of urd ⁇ nown etiology. It is not laiown, or beUeved, to have a microbiologic cause. Problem. s e.xperienced by those suffer. ing with psoriasis .include intense itctung .and discomfort, unsightly sldn ble.mishes and chrome scratching resulting skin . ⁇ ifections.
• the OXAZOL.LD.INO.NEs can be used to treat the inflammation and pain caused by arthritis, including those types of arthritis which are not caused by infection. This is important since all of the medications presently available to treat arthritis have severe side effects. Steroidal medications (glucocorticoids like prednisone and cortisol) give stomach ulcere, cataracts, reduced resistance to infection, weight gain and thinning of sldn. Non-steroidal anti-inflammatory drugs (NS.AIDS such as indomethacin or ibuprofen among other's) can cause stomach ulcers, reduced kidney function .and bone marrow effects. Chemotherapeutic agents (like methotrexate) can have severe adverse effects on bone ma ⁇ ow and liver function. The OX- AZOL.IDL. NO.NEs provide the oppor. tunity for relief of symptoms of inflammation for patients intolerant of other types of arthritis medications.
• the present invention prevents and reduces the amount of suppression of bone marrow and injury to intestinal crypt cells (the cells that produce new intestinal cells).
• intestinal crypt cells the cells that produce new intestinal cells.
• SUMM ⁇ Y OF INVENTION Disclosed is a method of treating a person who has psoriasis which comp.rises administeiing to the patient an anti-psoriasis effective amount of an oxazolidinone selected from the group consisting of:
• a method of reducing damage to hematopoietic ceUs and intestinal ceUs in a person be ⁇ g treated with one or more anti-cancer chemotherapeutic agents which compiises administering to the human an anti- cytotoxic effective amount of an oxazolidinone selected from the group consisting of the sxi oxazolidinones set forth above.
• Suitable pharmaceutical acceptable salts include the acid addition salts from the both inorganic and organic acids including hydrochloric, hydrobromic, sulfiiric, phosphoric, sulfonic acids, methanesulfonic, ghiconic, galacturonic, citratic, ox. ylatic and acetic. It is preferred that the person being treated for psoriasis or arthritis or with cancer chemotherapy agents with OXAZOLIDINONEs does not have a gram positive bacterial infection at the time of be g treated.
• the OXAZOLIDINONEs can either be used individually or in combination with each other or combination with non-OXAZOL.LDLNONEs.
• the OX. AZOLIDL. NONEs are administered orally, parenterally (TV), topically or rectally.
• the OXAZOLLDINONEs can be administered in tablet, capsule or liquid (suspension, syrup or solution) dosage form. Regardless of the dosage form, an anti-psoriasis effective amount of the OX ⁇ ZOLI. DINONEs is from about 50 mg to about 1,200 mg/day. It is preferred that the OXa AZOLIDINONEs be given in two or more divided doses, more preferably in two divided doses.
• the OXAZOLTOINONEs When administered parenterally, the OXAZOLTOINONEs should be admii ⁇ stered IV.
• the IV infusion should be adjusted such that the flow rate delivera an anti-psoriasis effective amount of from about 50 mg to about 1,200 mg day.
• (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- ox. azolidinyl]methyl]aceta ⁇ mde is v ⁇ ually 100% bioavailable. Therefore, the patient will acMeve approx. imately the same blood levels with the same dose regardless of whether it is given orally of parenterally.
• the OX. AZOL. JDI. NON. ES When applied topically, the OX. AZOL. JDI. NON. ES can be applied in many different phairmaceutical dosage forms all well known to those skilled in the art. These include as a solution, cream, ointment, gel, lotion, suspension or emulsion, etc. Regardless of the topical pharmaceutical dosage form selected, the concentration of the O.XAZOLIDINO.NES should be from about 0.01% to about 10% (wt/wt). .Regardless of the pharmaceutical dosage form, the topical formulation should be apphed one to four times dafly.
• the O.XAZOLIDINONEs When administered rectally, the O.XAZOLIDINONEs should be administered as a suppository which delivers an anti-psoriasis effective amount of from about 50 mg to about 1,200 mg day.
• the OaXAZOLIDINONEs When administered systemically, whether orally, parenterally or rectally the OaXAZOLIDINONEs should be ad.ministered either continuously or m cyclic courses of 7-28 days every 1 to 12 months. When administered topically, the O.XAZOLID.INO.NES should be applied either daily for 7 to 28 days every 1 - 12 months.
• the OXAZOLIDINONEs can either be used individually or in combination with each other or in combination with non-O.XAZOI DINONEs.
• the OXAZOL-LDINONEs are administered orally, parenterally (TV), topically or rectally.
• the O.X ⁇ OLIDINONEs When administered orally, the O.X ⁇ OLIDINONEs can be administered in t-ablet, capsule or liquid (suspension, syrup or solution) dosage form. .Regardless of the dosage form, .an anti-artliritis effective .amount of the OXAZOL.IDINONEs is from about 50 mg to about 1,200 mg day. It is prefeired that the OXa AZOLIDINONEs be given in two or more divided doses, more preferably in two divided doses.
• the OXi-iZOL.IDINO.NEs When administered parenterally, the OXi-iZOL.IDINO.NEs should be administered IV.
• the IV infusion should be adjusted such that the flow rate delivere an anti-arthritis effective amount of from about 50 mg to about 1,200 mg/day. This can be done by a continuous infusion, or as divided doses given as short term infusions of 30-90 minutes, preferably twice a day.
• OXAZO.LIDINO.NEs When applied topically, the OXAZO.LIDINO.NEs can be applied in many different pharmaceutical dosage forms all well .known to those sltiUed in the art. These include a solution, cream, ointment, gel, lotion, suspension or emulsion.
• O.XAZOLIDINONEs should be from about 0.01% to about 10% (wt wt). Regardless of the pharmaceutical dosage form, the topical formulation should be applied one to four times daily. When administered rectally, the OXAZOLffilNONEs should be adniiiiistered as a suppository wliich delivers an anti-arthritis effective amount of from about 50 mg to about 1,200 mg/day.
• QXAZOL.LDINO.NEs should be administered either continuously or in cyclic courses of 7-28 days every 1 to 12 months. When administered topically, the
• O.XAZOLIDINONEs should be applied either daily for 7 to 28 days every 1 - 12 months.
• OaXt-vZOLIDINONE used, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is weU known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the
• OXAZOLaLDINONE in the patient's blood and/or the patient's response to the parti-mlar condition being treated.
• .Individuals who have cancer and are treated with anti-cancer chemotherapeutic agents e-Eperience damage to their hematopoietic and mtestin ⁇ cells.
• the present method also prevents reduces damage to intestinal crypt cells. These are the cells located in the intestinal area that produce new intestinal cells.
• physicians can prevent or reduce the toxicity of the chemotherapeutic agents and therefore can treat cancer patients longer and or with higher doses and with reduced ⁇ sks of complications. .All this means a more successiveSaful outcome for the patient.
• the OXAZOLIDINONEs can either be used individually or in combination with each other or in combination with non-OXAZOLIDINONEs. In some cases the present method will prevent the damage from occurring and in other cases it will reduce the damage that would have occurred if the patient had not been treated with the OXAZO.LIDINO.NEs. As used here, reduction is a fo.rm of prevention; prevention is the ultimate reduction.
• the present method is practiced by preferably pre-treating the patient for about 2 to about 20 days prior to the patient being treated with an anti-cancer chemotherapeutic agent. It is more preferable that the pretreatment be from about 5 to about 7 days prior to the patient being treated with an anti-cancer chemotherapeutic agent. .
• the OXAZOLIDINONEs can be administered concurrently with the anti-cancer chemotherapeutic agent.
• Anti-cancer chemotherapeutic agents which are included in the method of reducing damage according to the present invention .are selected from four d.ifferent types of chemotherapeutic agents. These are:
• DNA-.interactive agents including alkylating agents, DNA strand- breakage agents, DNA topoisomerase I and II inhibitors, DNA minor groove binders
• DNA-.interactive agents such as chlorambucil, cyclophosphamide, thiotepa, busulfan, carmustine, cisplatin, carboplatin, mitomycin, procarbazine, bleomycin, amsacrine, dauno.rubicin, doxorubicin, etoposide, plicamycin, campothecin and ironotecan;
• tubulin-interactive agents such as vinblastine, vincristine and paclitaxel
• ho ⁇ nonal agents such as dienestrol, diethylstilbestrol, estradiol, tamo- ⁇ fon and fluOaXymesterone.
• the anti-cancer chemotherapeutic agent be selected from the group consisting of chlorambucil, cyclophosphamide, thiotepa, busnlfam, carmustine, cisplatin, carboplatin, mitomycin, procarbazine, bleomycin, amsacrine, daunorubicin, doxorubicin, etoposide, plicamycin, camptothecin, ironotecan, methotr ⁇ a ate, mercaptopurine, el ⁇ xuridine, fluorouracil, vinblastin, vincristine, pacHtaxel, dienestrol, diethylstilbestrol, estradiol, tamo.xifon and fluo.xymesterone. It is more preferred that the anti-cancer chemotherapeutic agent be selected from the group consisting of etoposide, irinotecan, fluorouricil and pac
• the OXAZOL.ID.INONEs are administered orally, parenterally (TV) or rectaUy. It is prefe ⁇ ed that the OX. AZO.HDI, NONEs be administered orally or by TV, more preferably orally.
• the OXAZOLIDLNQNEs can be administered in soHd (tablet or capsule) or .liquid (suspension, syrup or solution) dosage form. Regardless of the dosage form, a cytostatic or an anti-cytotoxic effective amount of the OXAZOLIDINONEs is from about 50 mg to about 1,200 mg/day. It is preferred that the OXAZOL.LD.INONEs be given in two or more divided doses, more preferably in two divided doses.
• the O.XAZOLID.LNO.NEs When administered parenterally, the O.XAZOLID.LNO.NEs should be administered IV.
• the TV infasion should be adjusted such that the flow rate delivers an anti-cytotoxic effective amount of from about 50 mg to about 1,200 mg/day. This can be done by a continuous infusion, or .as divided doses given as short term infusions of 30-90 minutes, preferably twice a day.
• the O.XAZOL.ID.INONES When administered rectally, the O.XAZOL.ID.INONES should be administered as a suppository which dehvers an anti-cytotoxic effective amount of from about 50 mg to about 1,200 mg day.
• the exact dosage and frequency of administration depends on the particular OXAZOL.IDINONE used, the particular anti-cancer chemotherapeutic agent used, the dose of the anti-cancer chemotherapeutic agent, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well .known to those skilled in the art and can be more accurately dete * rmined by measuring the blood level or concentration of the OXAZOLIDINO.NE in the patient's blood and/or the patient's response to the particular condition being treated. DEFalNITIONS A3STD CONVENTIONS
• compositions, formulation, stability, patient acceptance and bioavailability refera to those properties and/or substances which are acceptable to the patient from a pharmacological/to.xicological point of view and to the manufacturing pharmaceutical chemist from a physical chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
• the ratio of the solid to the solvent is weightvolume (wt v).
• % active ingredient of a pharmaceutical fo.rmulation is set forth, it is the ratio of the active ingredient of the entire pharmaceutteal formulation and is expressed as weight weight (wt wt).
• Alcohol refere to ethyl alcohol.
• OXAZO.LJDINONES refers to the compounds of EaXAJMPLES 1 thru 6.
• Anti-cytotoxic refers to reducing and/or preventing normal ceU death.
• the catalyst is then removed by filtration through Celite, and the filtrate is concentrated under reduced pressure and the residue chromatographed on silica gel (230 - 400 mesh, 350 g), eluting with a gradient of methsuiol/methylene chloride (3/97 - 7/93).
• l- ⁇ ButoaXycarbonyl-4-(2-fluoroethyl)-3-oxopiperazine (6.65 g) is dissolved in dichloromethane (500 ml), cooled in an ice-bath and tiifluoroacetic acid (150 ml) added. The mixture is stirred at the same temperature for 2 hours. The solvent is removed to give a crude product which is dissolved in the minim"TM volume of ethyl acetate. Slow addition of ether causes precipitation of l-(2-fluoroethyl)-2- oxopiperaz.ine as the mono tiifluoroacetic acid salt.
• a solution of lithium is prepared by addition of n-butyllithium (1.6 M in hexane, 2.9 ml) to a stirred solution of t-butanol (0.43 g) in anhydrous THF (10 ml) at -10° under argon. After cooling to -70°, a solution of 5- benzyloxycarbonylamino-2-(4-[2-fluoroethyl]-3-oxopiperazin-l-yl)fluorobenzene (1.5 g) in dry THF (15 ml) is added.

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Dermatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Physical Education & Sports Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (13)

Applications Claiming Priority (10)

Publications (1)

Family

ID=27535698

Family Applications (1)

Country Status (15)

Cited By (8)

Citations (4)

• 1998
  • 1998-11-10 SI SI9830387T patent/SI1032386T1/xx unknown
  • 1998-11-10 CN CNA2004100027903A patent/CN1546030A/zh active Pending
  • 1998-11-10 KR KR1020007005366A patent/KR100574307B1/ko not_active Expired - Fee Related
  • 1998-11-10 AU AU15823/99A patent/AU743941B2/en not_active Ceased
  • 1998-11-10 DK DK98960157T patent/DK1032386T3/da active
  • 1998-11-10 JP JP2000520777A patent/JP2001522886A/ja not_active Withdrawn
  • 1998-11-10 KR KR1020057017426A patent/KR100589545B1/ko not_active Expired - Fee Related
  • 1998-11-10 BR BR9815615-2A patent/BR9815615A/pt not_active Application Discontinuation
  • 1998-11-10 CN CNB988100134A patent/CN1142777C/zh not_active Expired - Fee Related
  • 1998-11-10 WO PCT/US1998/023233 patent/WO1999025344A1/en not_active Ceased
  • 1998-11-10 PT PT98960157T patent/PT1032386E/pt unknown
  • 1998-11-10 NZ NZ504612A patent/NZ504612A/xx unknown
  • 1998-11-10 CA CA002303961A patent/CA2303961A1/en not_active Abandoned
  • 1998-11-10 ES ES98960157T patent/ES2193592T3/es not_active Expired - Lifetime
  • 1998-11-10 AT AT98960157T patent/ATE233092T1/de not_active IP Right Cessation
  • 1998-11-10 DE DE69811717T patent/DE69811717T2/de not_active Expired - Fee Related
  • 1998-11-10 EP EP98960157A patent/EP1032386B1/en not_active Expired - Lifetime

Patent Citations (6)

Also Published As

Similar Documents

Legal Events